PADI4 and hepatocellular carcinoma: In the NASH-HCC model, NET inhibition using DNase I administration or PAD4 knockout decreased tumor growth in the liver, and this effect was explained by the altering of the inflammatory environment, decreasing of Treg levels, and activity in the liver, which in turn reduced tumor burden [172,311].